MDACC Study No:2012-0349 ( NCT No: NCT01723202)
Title:A Randomized Phase 2 Study of single agent GSK2118436 (BRAFi) vs. combination regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in patients with BRAF mutated thyroid carcinoma
Principal Investigator:Naifa L. Busaidy
Treatment Agent:Dabrafenib; Trametinib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if dabrafenib or the
combination of dabrafenib and trametinib can help to control thyroid cancer
that has a mutation or fusion in the BRAF gene. The safety of these drugs will
also be studied.

Dabrafenib is designed to block the mutated BRAF protein. By blocking the
protein, the drug may slow the growth of or kill cancer cells that have the

Trametinib is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:Dabrafenib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:National Comprehensive Cancer Network
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naifa L. Busaidy
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2841
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults